Description

Droloxifene Citrate

Droloxifene Citrate is a high-purity, pharmaceutical-grade selective estrogen receptor modulator (SERM) used in the development of hormone-related therapies, particularly for breast cancer and osteoporosis. As a structurally enhanced analogue of Tamoxifen, Droloxifene exhibits improved tissue selectivity, reduced estrogenic side effects, and favorable pharmacokinetics. Droloxifene Citrate

• Is a pharmaceutical-grade SERM for hormone receptor-positive breast cancer research
• Exhibits enhanced binding affinity and tissue selectivity versus tamoxifen
• Is suitable for oral solid dosage forms including tablets and capsules
• Has investigational use in oncology, osteoporosis, and hormone replacement modulation
• Is manufactured under Good Manufacturing Practice (GMP) conditions
• Is supplied with complete regulatory documentation including Certificate of Analysis (CoA) and supporting technical data

Chemically designated as (E)-4-[1-[2-(Dimethylamino)ethoxy]phenyl]-1-(4-hydroxyphenyl)-2-phenyl-1-buten-1-ol citrate, Droloxifene Citrate is a nonsteroidal compound that binds to estrogen receptors and modulates their activity depending on target tissue.

In pharmaceutical research and clinical development it is used in:

• Hormone receptor-positive breast cancer treatments, as a SERM with reduced uterotropic activity
• Osteoporosis therapy development, leveraging bone-selective estrogen receptor modulation
• Postmenopausal hormone replacement strategies, minimizing risk of endometrial proliferation
• Comparative pharmacology studies evaluating next-generation SERM candidates

Droloxifene has been shown to exert antiestrogenic effects in breast tissue while preserving beneficial estrogen-like effects on bone and lipid metabolism. Its reduced estrogenic stimulation in uterine tissue may offer an improved safety profile compared to Tamoxifen.

CarboMer supplies Droloxifene Citrate with stringent controls over chemical purity, polymorphic form, residual solvents, and impurity profile. Each lot is fully traceable and manufactured under GMP conditions for use in regulated R&D environments.

The material is packaged in sealed, light-resistant, tamper-evident containers. Available in research, preclinical, and pilot-scale quantities. Minimum order quantities (MOQ), lead times, and full documentation including analytical methods and CoAs are available upon request.

Each batch is tested for identity (NMR, IR, HPLC), assay, residual solvents, water content, and related substances. Certificates of Analysis (CoA), Safety Data Sheets (SDS), and regulatory support documents accompany every shipment.

As with all CarboMer investigational actives and hormone modulators, Droloxifene Citrate is backed by scientific expertise, formulation guidance, and dependable sourcing to support the advancement of novel endocrine and oncologic therapies.